Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Open Access
- 28 August 2019
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 6 (9) , 1815-1824
Abstract
Objective: To determine the cutoffs that optimized the agreement between 18F‐Florbetapir positron emission tomography (PET) and Aβ1‐42, Aβ1‐40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18F‐Florbetapir imaging.Methods: Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of Aβ1‐42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18F‐Florbetapir PET and evaluated concordance between markers of the amyloid category.Results: Aβ1‐42, tTau and pTau (but not Aβ1‐40) and the ratios with Aβ1‐42 had good diagnostic agreement with 18F‐Florbetapir PET. As a marker of amyloid pathology, the Aβ1‐42/Aβ1‐40 ratio had higher agreement and better correlation with amyloid PET than Aβ1‐42 alone.Interpretation: CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of Aβ1‐42 with Aβ1‐40 increases the agreement between markers of amyloid pathology.Keywords
All Related Versions
Funding Information
- Fundació la Marató de TV3 (20141210, 20142610, 20161431)
- Instituto de Salud Carlos III (PI13/01532, PI14/01126, PI14/01561, PI16/01825, PI17/01019, PI17/01895, PI18/00435)
- Agència de Gestió d’Ajuts Universitaris i de Recerca (2017‐SGR‐547, SLT006/17/119, SLT006/17/125, SLT006/17/95)
This publication has 28 references indexed in Scilit:
- CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisationClinica Chimica Acta, 2017
- CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer diseaseAnnals of Clinical and Translational Neurology, 2016
- Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric studyAlzheimer's Research & Therapy, 2015
- Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's diseaseNeurobiology of Aging, 2015
- Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer DiseaseJAMA Neurology, 2015
- The effect of beta‐amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signalHuman Brain Mapping, 2015
- Determining Cut-Points for Alzheimer’s Disease Biomarkers: Statistical Issues, Methods and ChallengesBiomarkers in Medicine, 2012
- Amyloid deposition, hypometabolism, and longitudinal cognitive declineAnnals of Neurology, 2012
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderlyAnnals of Neurology, 2009
- Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 loadJournal of Neurochemistry, 2006